We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cynthia Schnedar, director of CDER’s Office of Compliance, is leaving to pursue opportunities in the private sector, Janet Woodcock said Monday in an emailed message. Her last day will be March 18. Read More
European regulators have signed off on Teva Pharmaceutical Industries’ planned $40.5 billion purchase of Allergan’s generics unit, provided the company sells off numerous overlapping product areas to address anti-competitive concerns. Read More
Say “sayonara” to the status quo of pharmaceutical promotional review. That’s the consensus of industry experts weighing the implications of the FDA’s decision Tuesday to settle Amarin’s First Amendment lawsuit. Read More